Afatinib: A kinase inhibitor for treating non-small cell lung cancer
-
Healthcare professionals use the drug Afatinib in the treatment of metastatic Non-Small Cell Lung Cancer and metastatic squamous NSCLC. Afatinib is a tyrosine kinase inhibitor, and it covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) and irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of ErbB signaling. The medicine Afatinib is supplied as tablets in 20 mg, 30 mg, and 40 mg to administer orally via the mouth. The active ingredient in the tablets is Afatinib, with inactive ingredients lactose monohydrate, microcrystalline cellulose, crospovidone, colloidal silicon dioxide, and magnesium stearate.
One can find Afatinib with several generic medicine suppliers.